Overview
- GeneDx disclosed in its Q1 2026 results that it took about a $31.2 million impairment tied to its May 5, 2025 acquisition of Fabric Genomics, a charge that equals roughly 94% of the roughly $33.2 million cash purchase price.
- The impairment and a sudden downgrade to 2026 revenue guidance produced a roughly 49% collapse in GeneDx shares, a drop that investor complaints say erased about $33.42 per share.
- Plaintiffs say the company also revealed an unexpected shortfall in average reimbursement rate, driven by a product mix shift toward lower‑paying genome tests, which reduced ARR by about $200 versus prior expectations.
- Multiple law firms have filed complaints or solicited investors for a consolidated case that names CEO Katherine Stueland and CFO Kevin Feeley as individual defendants and seeks federal securities and control‑person claims.
- The litigation is in the early PSLRA stage with competing lead‑plaintiff motions due August 3, 2026 and possible next steps that include appointment of a lead plaintiff, discovery into executives' disclosures, and either settlement or a court decision on the merits.